Type 2 diabetes mellitus and CA 19-9 levels
Type 2 diabetes mellitus and CA 19-9 levels
复制标题
DOI：
10.3748/wjg.v13.i40.5357
复制
发表时间：
2007-10-28
影响因子：
4.3
通讯作者：
Mayadagli, Alpaslan
中科院分区：
文献类型：
--
作者：
Uygur-Bayramicli, Oya;Dabak, Resat;Mayadagli, Alpaslan
目的：为了前瞻性地研究2型糖尿病患者血清CA 19-9水平与年龄和性别匹配的对照subjects.METHODS：我们记录了糖尿病的持续时间，并检查了76例2型糖尿病患者和76例对照的空腹血糖水平，糖化血红蛋白水平和血清CA 19-9水平。结果：糖尿病组CA 19-9平均水平为46.0 ± 22.4U/mL，对照组为9.97 ± 7.1U/mL，两组比较有显著性差异（P < 0.001）。回归分析显示，糖尿病与CA 19-9呈正相关（t = 8.8，P <0.01），与年龄、性别、血糖、糖化血红蛋白无关。两名糖尿病患者因在初始评估时CT显示腹部恶性肿瘤而被排除在研究之外。对于所有患者，腹部CT显示没有胰腺abnormals.CONCLUSION：CA 19-9是一种肿瘤相关抗原，这是升高的胰腺癌，上消化道，卵巢肝细胞癌，结直肠癌，以及在炎症条件下的肝胆系统，胆道梗阻和甲状腺疾病。糖尿病被认为是胰腺癌的危险因素，胰腺癌的发病率正在增加，并且是所有癌症中存活率最低的癌症之一。CA 19-9用于胰腺癌的诊断，但也是可能由糖尿病引起的胰腺组织损伤的标志物。我们建议在糖尿病患者中应使用较高的CA 19-9临界值来区分良性和恶性胰腺疾病，糖尿病患者中CA 19-9的轻微升高应被视为胰腺外分泌功能障碍的指征。(C)2007年WJG。All rights reserved.
AIM: To prospectively investigate serum CA 19-9 levels in type 2 diabetic patients in comparison with age- and gender-matched control subjects.METHODS: We recorded duration of diabetes and examined fasting glucose levels, HbA1c levels and serum CA 19-9 levels in 76 type 2 diabetic patients and 76 controls. Abdominal CT was performed in order to eliminate abdominal malignancy in the diabetic and control groups.RESULTS: The average CA 19-9 level was 46.0 +/- 22.4 U/mL for diabetic patients whereas it was 9.97 +/- 7.1 U/mL for the control group (P < 0.001). Regression analysis showed a positive correlation between diabetes and CA 19-9 independent from age, gender, glucose level and HbA1c level (t = 8.8, P < 001). Two of the diabetic patients were excluded from the study because of abdominal malignancy shown by CT at the initial evaluation. For all patients, abdominal CT showed no pancreatic abnormalities.CONCLUSION: CA 19-9 is a tumor-associated antigen, which is elevated in pancreatic, upper gastrointestinal tract, ovarian hepatocellular, and colorectal cancers, as well as in inflammatory conditions of the hepatobiliary system, biliary obstruction and in thyroid diseases. Diabetes has been claimed to be a risk factor for pancreatic cancer, which is increasing its incidence and has one of the lowest survival rates of all cancers. CA 19-9 is used in the diagnosis of pancreatic cancer but is also a marker of pancreatic tissue damage that might be caused by diabetes. We propose that a higher cutoff value of CA 19-9 should be used in diabetics to differentiate benign and malignant pancreatic disease, and subtle elevations of CA 19-9 in diabetics should be considered as the indication of exocrine pancreatic dysfunction. (C) 2007 WJG. All rights reserved.